PubRank

Masato Tashiro

Author PubWeight™ 127.81‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The global circulation of seasonal influenza A (H3N2) viruses. Science 2008 10.05
2 Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob Agents Chemother 2006 4.02
3 Characterization of H7N9 influenza A viruses isolated from humans. Nature 2013 3.71
4 Influenza vaccine strain selection and recent studies on the global migration of seasonal influenza viruses. Vaccine 2008 2.56
5 Epidemiological, antigenic and genetic characteristics of seasonal influenza A(H1N1), A(H3N2) and B influenza viruses: basis for the WHO recommendation on the composition of influenza vaccines for use in the 2009-2010 northern hemisphere season. Vaccine 2009 2.48
6 Encephalitis and encephalopathy associated with an influenza epidemic in Japan. Clin Infect Dis 2002 2.38
7 Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques. Nat Med 2004 2.31
8 Pause on avian flu transmission research. Science 2012 2.24
9 Protease-mediated enhancement of severe acute respiratory syndrome coronavirus infection. Proc Natl Acad Sci U S A 2005 1.85
10 Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives. Lancet Infect Dis 2011 1.66
11 Development of H5-RT-LAMP (loop-mediated isothermal amplification) system for rapid diagnosis of H5 avian influenza virus infection. Vaccine 2006 1.61
12 Cross-protection against H5N1 influenza virus infection is afforded by intranasal inoculation with seasonal trivalent inactivated influenza vaccine. J Infect Dis 2007 1.56
13 Characterization of quasispecies of pandemic 2009 influenza A virus (A/H1N1/2009) by de novo sequencing using a next-generation DNA sequencer. PLoS One 2010 1.56
14 Virus infection triggers SUMOylation of IRF3 and IRF7, leading to the negative regulation of type I interferon gene expression. J Biol Chem 2008 1.44
15 The development and characterization of H5 influenza virus vaccines derived from a 2003 human isolate. Vaccine 2005 1.42
16 Neuraminidase inhibitor susceptibility network position statement: antiviral resistance in influenza A/H5N1 viruses. Antivir Ther 2005 1.33
17 Improving influenza vaccine virus selection: report of a WHO informal consultation held at WHO headquarters, Geneva, Switzerland, 14-16 June 2010. Influenza Other Respir Viruses 2011 1.32
18 Rapid diagnosis of H5N1 avian influenza virus infection by newly developed influenza H5 hemagglutinin gene-specific loop-mediated isothermal amplification method. J Virol Methods 2007 1.29
19 Molecular evolutionary analysis of the influenza A(H1N1)pdm, May-September, 2009: temporal and spatial spreading profile of the viruses in Japan. PLoS One 2010 1.28
20 WHO recommendations for the viruses to be used in the 2012 Southern Hemisphere Influenza Vaccine: epidemiology, antigenic and genetic characteristics of influenza A(H1N1)pdm09, A(H3N2) and B influenza viruses collected from February to September 2011. Vaccine 2012 1.23
21 Antigenic differences between H5N1 human influenza viruses isolated in 1997 and 2003. J Vet Med Sci 2004 1.21
22 Oseltamivir-resistant influenza viruses A (H1N1) during 2007-2009 influenza seasons, Japan. Emerg Infect Dis 2010 1.21
23 Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model. Vaccine 2007 1.19
24 Rapid detection of the severe acute respiratory syndrome (SARS) coronavirus by a loop-mediated isothermal amplification assay. Clin Chem 2004 1.16
25 Characterization of the amino acid residues of sendai virus C protein that are critically involved in its interferon antagonism and RNA synthesis down-regulation. J Virol 2004 1.15
26 Human H5N2 avian influenza infection in Japan and the factors associated with high H5N2-neutralizing antibody titer. J Epidemiol 2008 1.14
27 Genetically stable and fully effective smallpox vaccine strain constructed from highly attenuated vaccinia LC16m8. Proc Natl Acad Sci U S A 2005 1.13
28 Monitoring and characterization of oseltamivir-resistant pandemic (H1N1) 2009 virus, Japan, 2009-2010. Emerg Infect Dis 2011 1.12
29 A subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice. Int Immunol 2004 1.10
30 Importance of the anti-interferon capacity of Sendai virus C protein for pathogenicity in mice. J Virol 2007 1.09
31 The first autopsy case of pandemic influenza (A/H1N1pdm) virus infection in Japan: detection of a high copy number of the virus in type II alveolar epithelial cells by pathological and virological examination. Jpn J Infect Dis 2010 1.09
32 Transmission studies resume for avian flu. Science 2013 1.07
33 A two-year survey of the oseltamivir-resistant influenza A(H1N1) virus in Yamagata, Japan and the clinical effectiveness of oseltamivir and zanamivir. Virol J 2010 1.06
34 The host protease TMPRSS2 plays a major role in in vivo replication of emerging H7N9 and seasonal influenza viruses. J Virol 2014 1.05
35 Intranasal immunization with H5N1 vaccine plus Poly I:Poly C12U, a Toll-like receptor agonist, protects mice against homologous and heterologous virus challenge. Microbes Infect 2007 1.05
36 Wild-type measles virus induces large syncytium formation in primary human small airway epithelial cells by a SLAM(CD150)-independent mechanism. Virus Res 2003 1.05
37 Diagnostic significance of Aspergillus species isolated from respiratory samples in an adult pneumology ward. Med Mycol 2011 1.05
38 Productive infection in the murine central nervous system with avian influenza virus A (H5N1) after intranasal inoculation. Acta Neuropathol 2004 1.02
39 Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses. J Med Chem 2010 1.01
40 Mumps virus V protein antagonizes interferon without the complete degradation of STAT1. J Virol 2005 1.00
41 Seasonal influenza vaccine policies, recommendations and use in the World Health Organization's Western Pacific Region. Western Pac Surveill Response J 2013 0.99
42 The amino-terminal half of Sendai virus C protein is not responsible for either counteracting the antiviral action of interferons or down-regulating viral RNA synthesis. J Virol 2002 0.98
43 Protective immunity afforded by inactivated H5N1 (NIBRG-14) vaccine requires antibodies against both hemagglutinin and neuraminidase in mice. J Infect Dis 2009 0.96
44 Antigenic alteration of influenza B virus associated with loss of a glycosylation site due to host-cell adaptation. J Med Virol 2004 0.95
45 Multilocus sequence typing of Cryptococcus neoformans in non-HIV associated cryptococcosis in Nagasaki, Japan. Med Mycol 2012 0.95
46 One-step real-time reverse transcription-PCR assays for detecting and subtyping pandemic influenza A/H1N1 2009, seasonal influenza A/H1N1, and seasonal influenza A/H3N2 viruses. J Virol Methods 2010 0.95
47 Anti-influenza activity of phenethylphenylphthalimide analogs derived from thalidomide. Bioorg Med Chem 2010 0.94
48 Isolation of oseltamivir-resistant influenza A/H1N1 virus of different origins in Yokohama City, Japan, during the 2007-2008 influenza season. Jpn J Infect Dis 2009 0.93
49 Ebolavirus VP35 interacts with the cytoplasmic dynein light chain 8. J Virol 2009 0.93
50 Genotyping and phylogenetic analysis of the major genes in respiratory syncytial virus isolated from infants with bronchiolitis. Jpn J Infect Dis 2010 0.92
51 A novel combined adjuvant for nasal delivery elicits mucosal immunity to influenza in aging. Vaccine 2011 0.91
52 A molecular epidemiological study of respiratory viruses detected in Japanese children with acute wheezing illness. BMC Infect Dis 2011 0.89
53 Recombinant wild-type and edmonston strain measles viruses bearing heterologous H proteins: role of H protein in cell fusion and host cell specificity. J Virol 2002 0.89
54 Evaluation of influenza virus A/H3N2 and B vaccines on the basis of cross-reactivity of postvaccination human serum antibodies against influenza viruses A/H3N2 and B isolated in MDCK cells and embryonated hen eggs. Clin Vaccine Immunol 2012 0.89
55 Intranasal administration of adjuvant-combined recombinant influenza virus HA vaccine protects mice from the lethal H5N1 virus infection. Microbes Infect 2006 0.89
56 Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia. J Med Virol 2010 0.89
57 PolyI:polyC12U adjuvant-combined intranasal vaccine protects mice against highly pathogenic H5N1 influenza virus variants. Vaccine 2009 0.89
58 Expansion of the global measles and rubella laboratory network 2005-09. J Infect Dis 2011 0.88
59 Intranasal administration of adjuvant-combined vaccine protects monkeys from challenge with the highly pathogenic influenza A H5N1 virus. J Med Virol 2010 0.88
60 Molecular evolution of attachment glycoprotein (G) gene in human respiratory syncytial virus detected in Japan 2008-2011. Infect Genet Evol 2013 0.88
61 Phylogenetic and cluster analysis of human rhinovirus species A (HRV-A) isolated from children with acute respiratory infections in Yamagata, Japan. Virus Res 2009 0.87
62 High yield production of influenza virus in Madin Darby canine kidney (MDCK) cells with stable knockdown of IRF7. PLoS One 2013 0.86
63 Inactivated and adjuvanted whole-virion clade 2.3.4 H5N1 pre-pandemic influenza vaccine possesses broad protective efficacy against infection by heterologous clades of highly pathogenic H5N1 avian influenza virus in mice. Vaccine 2011 0.86
64 Improving influenza vaccine virus selection: report of a WHO informal consultation held at WHO headquarters, Geneva, Switzerland, 14-16 June 2010. Influenza Other Respir Viruses 2013 0.85
65 Characterization of neuraminidase inhibitor-resistant influenza A(H1N1)pdm09 viruses isolated in four seasons during pandemic and post-pandemic periods in Japan. Influenza Other Respir Viruses 2013 0.85
66 Molecular epidemiology of the attachment glycoprotein (G) gene in respiratory syncytial virus in children with acute respiratory infection in Japan in 2009/2010. J Med Microbiol 2012 0.85
67 Diagnosis of human respiratory syncytial virus infection using reverse transcription loop-mediated isothermal amplification. J Virol Methods 2006 0.85
68 Antiviral effects of Psidium guajava Linn. (guava) tea on the growth of clinical isolated H1N1 viruses: its role in viral hemagglutination and neuraminidase inhibition. Antiviral Res 2012 0.84
69 Recombinant nucleocapsid protein-based IgG enzyme-linked immunosorbent assay for the serological diagnosis of SARS. J Virol Methods 2005 0.84
70 Evaluation of a novel vesicular stomatitis virus pseudotype-based assay for detection of neutralizing antibody responses to SARS-CoV. J Med Virol 2006 0.84
71 Genetics and infectivity of H5N1 highly pathogenic avian influenza viruses isolated from chickens and wild birds in Japan during 2010-11. Virus Res 2012 0.84
72 Rapid detection of the S247N neuraminidase mutation in influenza A(H1N1)pdm09 virus by one-step duplex RT-PCR assay. J Virol Methods 2012 0.83
73 Isolation of influenza A H1N2 viruses from an outbreak in Yokohama City during the 2001-2002 influenza season in Japan. Jpn J Infect Dis 2003 0.83
74 Immunological detection of severe acute respiratory syndrome coronavirus by monoclonal antibodies. Jpn J Infect Dis 2005 0.83
75 Newly established monoclonal antibodies for immunological detection of H5N1 influenza virus. Jpn J Infect Dis 2012 0.83
76 Intranasal vaccination with an inactivated whole influenza virus vaccine induces strong antibody responses in serum and nasal mucus of healthy adults. Hum Vaccin Immunother 2013 0.82
77 A prime-boost vaccination of mice with heterologous H5N1 strains. Vaccine 2009 0.82
78 Cyclosporin A inhibits the propagation of influenza virus by interfering with a late event in the virus life cycle. Jpn J Infect Dis 2013 0.82
79 Reduced susceptibility to all neuraminidase inhibitors of influenza H1N1 viruses with haemagglutinin mutations and mutations in non-conserved residues of the neuraminidase. J Antimicrob Chemother 2013 0.82
80 Cell tropism of wild-type measles virus is affected by amino acid substitutions in the P, V and M proteins, or by a truncation in the C protein. J Gen Virol 2004 0.82
81 Immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1, NIBRG-14) vaccine administered by intramuscular or subcutaneous injection. Microbiol Immunol 2010 0.82
82 Influenza A whole virion vaccine induces a rapid reduction of peripheral blood leukocytes via interferon-α-dependent apoptosis. Vaccine 2013 0.82
83 Pathology and virus dispersion in cynomolgus monkeys experimentally infected with severe acute respiratory syndrome coronavirus via different inoculation routes. Int J Exp Pathol 2007 0.82
84 Rapid discrimination of oseltamivir-resistant 275Y and -susceptible 275H substitutions in the neuraminidase gene of pandemic influenza A/H1N1 2009 virus by duplex one-step RT-PCR assay. J Med Virol 2011 0.82
85 Development of vaccines and passive immunotherapy against SARS corona virus using SCID-PBL/hu mouse models. Vaccine 2007 0.82
86 Differences in the priming effect of various clades/subclades of inactivated H5N1 vaccine for booster injection with heterologous clades of vaccine strains. Vaccine 2011 0.81
87 Zymosan enhances the mucosal adjuvant activity of poly(I:C) in a nasal influenza vaccine. J Med Virol 2010 0.81
88 Development of a particle agglutination assay system for detecting Japanese encephalitis virus-specific human IgM, using hydroxyapatite-coated nylon beads. J Virol Methods 2002 0.81
89 Induction of protective immunity against severe acute respiratory syndrome coronavirus (SARS-CoV) infection using highly attenuated recombinant vaccinia virus DIs. Virology 2006 0.81
90 A single E105K mutation far from the active site of influenza B virus neuraminidase contributes to reduced susceptibility to multiple neuraminidase-inhibitor drugs. Biochem Biophys Res Commun 2012 0.80
91 Differences in clinical manifestations of influenza-associated encephalopathy by age. Microbiol Immunol 2009 0.80
92 Pandemic flu: from the front lines. Interviewed by Declan Butler. Nature 2009 0.80
93 Mechanisms of the action of povidone-iodine against human and avian influenza A viruses: its effects on hemagglutination and sialidase activities. Virol J 2009 0.80
94 Characterization of neutralizing antibodies in adults after intranasal vaccination with an inactivated influenza vaccine. J Med Virol 2012 0.80
95 The development of vaccines against SARS corona virus in mice and SCID-PBL/hu mice. Vaccine 2005 0.79
96 Development of a sensitive novel diagnostic kit for the highly pathogenic avian influenza A (H5N1) virus. BMC Infect Dis 2014 0.79
97 Evaluation of reverse transcription loop-mediated isothermal amplification assays for rapid diagnosis of pandemic influenza A/H1N1 2009 virus. J Med Virol 2011 0.79
98 A case series of chronic necrotizing pulmonary aspergillosis and a new proposal. Jpn J Infect Dis 2013 0.78
99 Development of a diagnostic system for novel influenza A(H7N9) virus using a real-time RT-PCR assay in Japan. Jpn J Infect Dis 2014 0.78
100 Development of an assay for the detection and quantification of the measles virus nucleoprotein (N) gene using real-time reverse transcriptase PCR. J Med Microbiol 2009 0.78
101 Novel reassortant influenza A(H1N2) virus derived from A(H1N1)pdm09 virus isolated from swine, Japan, 2012. Emerg Infect Dis 2013 0.78
102 Cross-protective immunity against influenza virus infections induced by intranasal vaccination together with a TLR3-mucosal adjuvant. Hum Vaccin 2011 0.78
103 Detection sensitivity of influenza rapid diagnostic tests. Microbiol Immunol 2014 0.77
104 Novel Reassortant Avian Influenza A(H5N1) Virus in Human, Southern Vietnam, 2014. Emerg Infect Dis 2016 0.77
105 Phylogenetic analysis of human bocavirus (HBoV) detected from children with acute respiratory infection in Japan. J Infect 2009 0.77
106 Prophylactic effects of chitin microparticles on highly pathogenic H5N1 influenza virus. J Med Virol 2007 0.77
107 Mechanism of drug resistance of hemagglutinin of influenza virus and potent scaffolds inhibiting its function. ACS Chem Biol 2012 0.77
108 NS1-binding protein abrogates the elevation of cell viability by the influenza A virus NS1 protein in association with CRKL. Biochem Biophys Res Commun 2013 0.77
109 Molecular analysis of genome of the pandemic influenza A(H1N1) 2009 virus associated with fatal infections in Gunma, Tochigi, Yamagata, and Yamaguchi prefectures in Japan during the first pandemic wave. Jpn J Infect Dis 2012 0.77
110 Management of chronic pulmonary aspergillosis. Ann N Y Acad Sci 2012 0.76
111 Timely production of A/Fujian-like influenza vaccine matching the 2003-2004 epidemic strain may have been possible using Madin-Darby canine kidney cells. Vaccine 2008 0.76
112 Treatment of mediastinitis due to methicillin-resistant Staphylococcus aureus in a renal dysfunction patient undergoing adjustments to the linezolid dose. Intern Med 2015 0.75
113 Relapsed Pulmonary Cryptococcosis during Tumor Necrosis Factor α Inhibitor Treatment. Intern Med 2016 0.75
114 Recurrent Streptococcus agalactiae Toxic Shock Syndrome Triggered by a Tumor Necrosis Factor-α Inhibitor. Intern Med 2016 0.75
115 Pulmonary Nocardiosis Caused by Nocardia concava with a Literature Review. Intern Med 2016 0.75
116 Pathological and virological analyses of severe acute respiratory syndrome-associated coronavirus infections in experimental animals. Adv Exp Med Biol 2006 0.75
117 Composition of hemagglutinin and neuraminidase affects the antigen yield of influenza A(H1N1)pdm09 candidate vaccine viruses. Jpn J Infect Dis 2013 0.75
118 Enhancement of SARS-CoV infection by proteases. Adv Exp Med Biol 2006 0.75
119 Non Susceptibility of Neonatal and Adult Rats against the Middle East Respiratory Syndrome Coronavirus. Jpn J Infect Dis 2016 0.75
120 [Round table discussion on highly pathogenic H5N1 avian influenza]. Uirusu 2004 0.75
121 [Isolation rate and susceptibilities of candida species from blood, vascular catheter, urine and stool]. Kansenshogaku Zasshi 2012 0.75
122 [Genetic analyses of viral diseases and their clinical applications]. Nihon Rinsho 2010 0.75
123 Successful Treatment of Aspergillus Empyema Using Open Window Thoracostomy Salvage Treatment and the Local Administration of an Antifungal Agent. Intern Med 2016 0.75
124 Seroprevalence of a novel influenza A (H3N2) variant virus in the Japanese population. Jpn J Infect Dis 2013 0.75
125 [Current topics on H7N9]. Uirusu 2013 0.75
126 Development of vaccines and passive immunotherapy against SARS coronavirus using mouse and SCID-PBL/hu mouse models. Adv Exp Med Biol 2006 0.75
127 Highly attenuated vaccinia virus DIs as a potential SARS vaccine. Adv Exp Med Biol 2006 0.75
128 Mutations at the monomer-monomer interface away from the active site of influenza B virus neuraminidase reduces susceptibility to neuraminidase inhibitor drugs. J Infect Chemother 2013 0.75
129 [Current situation in human infections with highly pathogenic avian influenza viruses]. Nihon Rinsho 2010 0.75